Author:
Bodet-Milin Caroline,Morvant Cyrille,Carlier Thomas,Frecon Gauthier,Tournilhac Olivier,Safar Violaine,Kraeber-Bodere Françoise,Le Gouill Steven,Macintyre Elizabeth,Bailly Clément
Abstract
AbstractThe prognostic value of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) at baseline or the predictive value of minimal residual disease (MRD) detection appear as potential tools to improve mantle cell lymphoma (MCL) patients’ management. The LyMa-101, a phase 2 trial of the LYSA group (ClinicalTrials.gov:NCT02896582) reported induction therapy with obinutuzumab, a CD20 monoclonal antibody. Herein, we investigated the added prognostic value of radiomic features (RF) derived from FDG-PET/CT at diagnosis for MRD value prediction. FDG-PET/CT of 59 MCL patients included in the LyMa-101 trial have been independently, blindly and centrally reviewed. RF were extracted from the disease area with the highest uptake and from the total metabolic tumor volume (TMTV). Two models of machine learning were used to compare several combinations for prediction of MRD before autologous stem cell transplant consolidation (ASCT). Each algorithm was generated with or without constrained feature selections for clinical and laboratory parameters. Both algorithms showed better discrimination performances for negative vs positive MRD in the lesion with the highest uptake than in the TMTV. The constrained use of clinical and biological features showed a clear loss in sensitivity for the prediction of MRD status before ASCT, regardless of the machine learning model. These data plead for the importance of FDG-PET/CT RF compared to clinical and laboratory parameters and also reinforced the previously made hypothesis that the prognosis of the disease in MCL patients is linked to the most aggressive contingent, within the lesion with the highest uptake.
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Dreyling, M. et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28, iv62–iv71 (2017).
2. Jung, D., Jain, P., Yao, Y. & Wang, M. Advances in the assessment of minimal residual disease in mantle cell lymphoma. J. Hematol. Oncol. 13, 127 (2020).
3. Pott, C. et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: A European MCL intergroup study. Blood 115, 3215–3223 (2010).
4. Bailly, C. et al. Interest of FDG-PET in the management of mantle cell lymphoma. Front. Med. 6, 70 (2019).
5. Carlier, T. et al. Quantification of intratumor heterogeneity derived from baseline FDG PET/CT in untreated mantle cell lymphoma patients enrolled in a prospective phase III trial of the LYSA group: Preliminary results. J. Nucl. Med. 56, 429–429 (2015).